 Ashley Frazer-Abel
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 14 | 2022 | 319 | 3.860 |
Why?
| | Complement Activation | 11 | 2022 | 385 | 1.090 |
Why?
| | Laboratories | 3 | 2024 | 109 | 1.040 |
Why?
| | Immunoassay | 2 | 2021 | 108 | 0.750 |
Why?
| | Clinical Laboratory Techniques | 2 | 2018 | 94 | 0.650 |
Why?
| | Complement Factor B | 5 | 2025 | 109 | 0.620 |
Why?
| | Laboratories, Hospital | 1 | 2018 | 14 | 0.600 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 97 | 0.570 |
Why?
| | RNA, Transfer | 3 | 2008 | 130 | 0.530 |
Why?
| | Angioedemas, Hereditary | 2 | 2014 | 4 | 0.490 |
Why?
| | Macular Degeneration | 3 | 2022 | 159 | 0.460 |
Why?
| | RNA | 3 | 2008 | 877 | 0.430 |
Why?
| | Autoimmune Diseases | 4 | 2022 | 428 | 0.410 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 756 | 0.410 |
Why?
| | Anticodon | 3 | 2004 | 24 | 0.400 |
Why?
| | Nucleic Acid Conformation | 4 | 2008 | 706 | 0.390 |
Why?
| | Angioedema | 1 | 2011 | 16 | 0.360 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2021 | 109 | 0.360 |
Why?
| | Emergency Responders | 2 | 2021 | 35 | 0.350 |
Why?
| | Oligonucleotides, Antisense | 2 | 2025 | 112 | 0.340 |
Why?
| | Immunologic Tests | 2 | 2021 | 16 | 0.320 |
Why?
| | Cyclin-Dependent Kinase 4 | 3 | 2006 | 44 | 0.320 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 179 | 0.310 |
Why?
| | T-Lymphocytes | 3 | 2009 | 1937 | 0.310 |
Why?
| | Autoantibodies | 3 | 2021 | 1468 | 0.310 |
Why?
| | Specimen Handling | 2 | 2022 | 163 | 0.310 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2019 | 130 | 0.300 |
Why?
| | Humans | 49 | 2025 | 129847 | 0.290 |
Why?
| | Arthritis, Rheumatoid | 3 | 2021 | 1098 | 0.270 |
Why?
| | Kidney Diseases | 2 | 2021 | 382 | 0.270 |
Why?
| | Smoking | 3 | 2019 | 1502 | 0.270 |
Why?
| | Tars | 1 | 2006 | 4 | 0.260 |
Why?
| | Nicotine | 2 | 2009 | 304 | 0.250 |
Why?
| | Complement Factor H | 2 | 2019 | 73 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 40 | 0.250 |
Why?
| | Complement Pathway, Alternative | 2 | 2025 | 120 | 0.250 |
Why?
| | Thionucleotides | 1 | 2025 | 34 | 0.240 |
Why?
| | Complement C3a | 3 | 2019 | 41 | 0.230 |
Why?
| | Cell Cycle | 2 | 2006 | 583 | 0.230 |
Why?
| | RNA, Transfer, Ser | 2 | 2008 | 4 | 0.230 |
Why?
| | B-Cell Activating Factor | 1 | 2024 | 21 | 0.230 |
Why?
| | Complement Factor D | 1 | 2024 | 30 | 0.230 |
Why?
| | Nuclear Proteins | 3 | 2004 | 660 | 0.220 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 66 | 0.210 |
Why?
| | Scleroderma, Systemic | 1 | 2024 | 114 | 0.210 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2023 | 19 | 0.210 |
Why?
| | Quality Control | 2 | 2021 | 162 | 0.210 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 20 | 0.210 |
Why?
| | Disease Susceptibility | 4 | 2020 | 334 | 0.210 |
Why?
| | Vitreous Body | 2 | 2022 | 109 | 0.210 |
Why?
| | Trichloroethylene | 1 | 2022 | 7 | 0.200 |
Why?
| | Protein Aggregates | 2 | 2019 | 67 | 0.190 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 26 | 0.190 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 129 | 0.190 |
Why?
| | Complement Inactivator Proteins | 1 | 2021 | 41 | 0.180 |
Why?
| | Extracellular Traps | 1 | 2021 | 49 | 0.180 |
Why?
| | Cross Reactions | 1 | 2021 | 133 | 0.180 |
Why?
| | Europe | 2 | 2020 | 363 | 0.180 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.180 |
Why?
| | Immunologic Factors | 2 | 2022 | 229 | 0.180 |
Why?
| | Retinal Drusen | 1 | 2021 | 31 | 0.180 |
Why?
| | Magnesium | 4 | 2008 | 155 | 0.170 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1441 | 0.170 |
Why?
| | Transcription Factors | 4 | 2004 | 1645 | 0.170 |
Why?
| | Sputum | 1 | 2021 | 302 | 0.160 |
Why?
| | Polyvinyl Chloride | 1 | 2019 | 8 | 0.160 |
Why?
| | Diethylhexyl Phthalate | 1 | 2019 | 15 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 37 | 0.160 |
Why?
| | Biomarkers | 4 | 2024 | 3971 | 0.160 |
Why?
| | Complement C3 | 2 | 2019 | 208 | 0.150 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 367 | 0.150 |
Why?
| | Wet Macular Degeneration | 1 | 2019 | 45 | 0.150 |
Why?
| | Biological Products | 1 | 2022 | 207 | 0.150 |
Why?
| | Rheumatoid Factor | 1 | 2019 | 167 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 55 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2022 | 302 | 0.150 |
Why?
| | Geographic Atrophy | 1 | 2019 | 68 | 0.150 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 94 | 0.150 |
Why?
| | Mass Spectrometry | 1 | 2021 | 717 | 0.150 |
Why?
| | Complement Inactivating Agents | 1 | 2017 | 47 | 0.140 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 69 | 0.130 |
Why?
| | Complement C3 Nephritic Factor | 1 | 2016 | 1 | 0.130 |
Why?
| | Inflammation | 4 | 2021 | 2748 | 0.130 |
Why?
| | Complement C5 | 1 | 2016 | 78 | 0.130 |
Why?
| | Riboflavin | 1 | 2016 | 7 | 0.130 |
Why?
| | Virus Inactivation | 1 | 2016 | 11 | 0.130 |
Why?
| | Ebolavirus | 1 | 2016 | 34 | 0.120 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2016 | 35 | 0.120 |
Why?
| | Critical Illness | 1 | 2021 | 759 | 0.120 |
Why?
| | Blood | 1 | 2016 | 105 | 0.120 |
Why?
| | RNA, Fungal | 3 | 2008 | 67 | 0.120 |
Why?
| | Animals | 11 | 2022 | 35409 | 0.120 |
Why?
| | Base Sequence | 4 | 2008 | 2142 | 0.120 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2015 | 43 | 0.120 |
Why?
| | Nanoparticles | 1 | 2019 | 376 | 0.120 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2014 | 11 | 0.120 |
Why?
| | RNA, Transfer, Phe | 2 | 2008 | 9 | 0.120 |
Why?
| | Oligoribonucleotides | 1 | 2014 | 52 | 0.110 |
Why?
| | Autoimmunity | 1 | 2020 | 863 | 0.110 |
Why?
| | Disinfection | 1 | 2016 | 117 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 3 | 2004 | 634 | 0.110 |
Why?
| | Male | 17 | 2025 | 63759 | 0.110 |
Why?
| | Birefringence | 3 | 2004 | 6 | 0.110 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 338 | 0.110 |
Why?
| | Female | 18 | 2025 | 68829 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 791 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1003 | 0.110 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 383 | 0.100 |
Why?
| | Antibodies, Viral | 3 | 2022 | 602 | 0.100 |
Why?
| | Middle Aged | 11 | 2025 | 31177 | 0.100 |
Why?
| | Comprehension | 1 | 2014 | 165 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2012 | 29 | 0.100 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 126 | 0.100 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2833 | 0.100 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | Cattle | 2 | 2008 | 978 | 0.090 |
Why?
| | Complement C4 | 1 | 2011 | 25 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2062 | 0.090 |
Why?
| | Aged | 8 | 2024 | 22107 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 157 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2020 | 3384 | 0.090 |
Why?
| | Mutation | 2 | 2020 | 3706 | 0.080 |
Why?
| | Oligonucleotides | 2 | 2014 | 146 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 505 | 0.080 |
Why?
| | Complement C5a | 2 | 2019 | 70 | 0.080 |
Why?
| | Drug Packaging | 2 | 2019 | 41 | 0.080 |
Why?
| | Adult | 9 | 2025 | 35634 | 0.070 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 121 | 0.070 |
Why?
| | Particle Size | 2 | 2019 | 355 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 179 | 0.070 |
Why?
| | Phenotype | 3 | 2022 | 3062 | 0.070 |
Why?
| | Disease Progression | 3 | 2024 | 2628 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 353 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2006 | 4102 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1434 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2022 | 851 | 0.070 |
Why?
| | NFATC Transcription Factors | 2 | 2004 | 86 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2012 | 1110 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3630 | 0.070 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2006 | 15 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1086 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.060 |
Why?
| | G1 Phase | 1 | 2006 | 69 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2025 | 1877 | 0.060 |
Why?
| | Macaca fascicularis | 2 | 2016 | 63 | 0.060 |
Why?
| | Temperature | 1 | 2008 | 635 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 96 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7066 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 836 | 0.060 |
Why?
| | Risk Factors | 3 | 2024 | 9801 | 0.060 |
Why?
| | Hemangiosarcoma | 1 | 2004 | 21 | 0.050 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2004 | 88 | 0.050 |
Why?
| | Dog Diseases | 1 | 2004 | 51 | 0.050 |
Why?
| | Plasmids | 1 | 2004 | 360 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 96 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 33 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 297 | 0.050 |
Why?
| | Antibodies, Antinuclear | 1 | 2022 | 66 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 104 | 0.050 |
Why?
| | Cytokines | 2 | 2012 | 2022 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 110 | 0.050 |
Why?
| | United States | 1 | 2018 | 13913 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 164 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2004 | 2703 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 305 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4410 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2024 | 520 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2002 | 2545 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 131 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 106 | 0.040 |
Why?
| | Apoptosis | 1 | 2009 | 2489 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 528 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 276 | 0.040 |
Why?
| | Vitrectomy | 1 | 2020 | 66 | 0.040 |
Why?
| | RNA, Bacterial | 1 | 2001 | 182 | 0.040 |
Why?
| | Complement C4a | 1 | 2019 | 9 | 0.040 |
Why?
| | Plasticizers | 1 | 2019 | 14 | 0.040 |
Why?
| | Freezing | 1 | 2019 | 87 | 0.040 |
Why?
| | Syringes | 1 | 2019 | 43 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 51 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 97 | 0.040 |
Why?
| | South Carolina | 1 | 2019 | 40 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 131 | 0.040 |
Why?
| | Cations, Divalent | 1 | 1999 | 53 | 0.040 |
Why?
| | Drug Stability | 1 | 2019 | 161 | 0.040 |
Why?
| | Rheology | 1 | 2019 | 91 | 0.040 |
Why?
| | Yeasts | 1 | 1999 | 52 | 0.040 |
Why?
| | Protein Stability | 1 | 2019 | 162 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2378 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 143 | 0.040 |
Why?
| | Young Adult | 3 | 2025 | 12467 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 110 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 400 | 0.040 |
Why?
| | Calcium | 1 | 2004 | 1212 | 0.040 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 39 | 0.040 |
Why?
| | Body Mass Index | 2 | 2019 | 2274 | 0.040 |
Why?
| | Mice | 3 | 2022 | 16983 | 0.040 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 19 | 0.040 |
Why?
| | HIV Infections | 1 | 2012 | 2730 | 0.040 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 15 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1161 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 186 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2019 | 467 | 0.030 |
Why?
| | Prolactin | 1 | 1997 | 97 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 85 | 0.030 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 1213 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 482 | 0.030 |
Why?
| | Escherichia coli | 1 | 2001 | 766 | 0.030 |
Why?
| | Epitopes | 1 | 2019 | 474 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 422 | 0.030 |
Why?
| | Jurkat Cells | 2 | 2009 | 134 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 548 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 169 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 738 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 592 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1022 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2739 | 0.030 |
Why?
| | Adolescent | 4 | 2016 | 20451 | 0.030 |
Why?
| | Vero Cells | 1 | 2016 | 66 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 759 | 0.030 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2020 | 743 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2724 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2017 | 247 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 391 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2014 | 2057 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 318 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1383 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1465 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 1997 | 317 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 1989 | 0.030 |
Why?
| | Signal Transduction | 3 | 2009 | 4935 | 0.030 |
Why?
| | Child | 3 | 2021 | 20962 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 304 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1997 | 383 | 0.030 |
Why?
| | Binding Sites | 3 | 2002 | 1251 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2330 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2024 | 1897 | 0.030 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 11 | 0.030 |
Why?
| | CD4-CD8 Ratio | 1 | 2012 | 22 | 0.030 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 19 | 0.020 |
Why?
| | Raltegravir Potassium | 1 | 2012 | 17 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 25 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2012 | 43 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 47 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1644 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1514 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 790 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3161 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4896 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5085 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 267 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 449 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2012 | 349 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2016 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 199 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 2009 | 4 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7158 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6550 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1617 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 594 | 0.020 |
Why?
| | Transfection | 2 | 2002 | 918 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1597 | 0.020 |
Why?
| | Receptors, Nicotinic | 1 | 2009 | 329 | 0.020 |
Why?
| | HIV-1 | 1 | 2012 | 839 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 855 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1058 | 0.020 |
Why?
| | Ploidies | 1 | 2004 | 17 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 154 | 0.010 |
Why?
| | Protein Binding | 2 | 2001 | 2123 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 385 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 98 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 455 | 0.010 |
Why?
| | Luciferases | 1 | 2002 | 147 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2002 | 266 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 524 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 487 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 14553 | 0.010 |
Why?
| | Cyclosporine | 1 | 2002 | 263 | 0.010 |
Why?
| | Exons | 1 | 2002 | 341 | 0.010 |
Why?
| | Tacrolimus | 1 | 2002 | 193 | 0.010 |
Why?
| | Base Pairing | 1 | 2001 | 61 | 0.010 |
Why?
| | Histone Deacetylases | 1 | 2002 | 212 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2002 | 366 | 0.010 |
Why?
| | Lymphocytes | 1 | 2002 | 377 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 954 | 0.010 |
Why?
| | RNA Stability | 1 | 2001 | 103 | 0.010 |
Why?
| | Ribosomes | 1 | 2001 | 165 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 10522 | 0.010 |
Why?
| | Models, Genetic | 1 | 2002 | 592 | 0.010 |
Why?
| | Cell Movement | 1 | 2004 | 950 | 0.010 |
Why?
| | Chromatin | 1 | 2002 | 478 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1716 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1997 | 24 | 0.010 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.010 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 1997 | 19 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 45 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 902 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 53 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2002 | 2135 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 182 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1997 | 50 | 0.010 |
Why?
| | Coenzymes | 1 | 1997 | 20 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1724 | 0.010 |
Why?
| | Catalysis | 1 | 1997 | 312 | 0.010 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 1997 | 68 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 3185 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1997 | 130 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 259 | 0.010 |
Why?
| | Mediator Complex | 1 | 1997 | 57 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1488 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 931 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1997 | 431 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 493 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5487 | 0.000 |
Why?
|
|
Frazer-Abel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|